Key result
Adding hiPSC-derived cardiac fibroblasts to engineered heart tissues increases contractile force ~5-fold.
Why the study?
Animal models are limited by species-dependent differences in cellular physiology, while standard stem cell models lack non-myocyte cell types like cardiac fibroblasts needed to mimic the human myocardial microenvironment.
Does incorporating quiescent hiPSC-derived cardiac fibroblasts into hiPSC-derived cardiomyocyte engineered heart tissues improve tissue compaction and contractile function compared to cardiomyocytes alone?
Does incorporating quiescent hiPSC-derived cardiac fibroblasts into hiPSC-derived cardiomyocyte engineered heart tissues improve tissue compaction and contractile function compared to cardiomyocytes alone?
This protocol establishes an isogenic 3D human engineered heart tissue model combining hiPSC-derived cardiomyocytes and quiescent cardiac fibroblasts that enhances tissue maturity and contractility while offering a human-relevant alternative to animal models for studying cardiac fibrosis and cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May enhance hiPSC-EHT contractility in vitro; leaves open translation to clinical cardiac models.
<ns3:p> Animal models have proven integral to broadening our understanding of complex cardiac diseases but have been hampered by significant species-dependent differences in cellular physiology. Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have shown great promise in the modelling of cardiac diseases despite limitations in functional and structural maturity. 3D stem cell-derived cardiac models represent a step towards mimicking the intricate microenvironment present in the heart as an <ns3:italic>in vitro</ns3:italic> model. Incorporation of non-myocyte cell types, such as cardiac fibroblasts, into engineered heart tissue models (EHTs) can help better recapitulate the cell-to-cell and cell-to-matrix interactions present in the human myocardium. Integration of human-induced pluripotent stem cell-derived cardiac fibroblasts (hiPSC-CFs) and hiPSC-CM into EHT models enables the generation of a genetically homogeneous modelling system capable of exploring the abstruse structural and electrophysiological interplay present in cardiac pathophysiology. Furthermore, the construction of more physiologically relevant 3D cardiac models offers great potential in the replacement of animals in heart disease research. Here we describe efficient and reproducible protocols for the differentiation of hiPSC-CMs and hiPSC-CFs and their subsequent assimilation into EHTs. The resultant EHT consists of longitudinally arranged iPSC-CMs, incorporated alongside hiPSC-CFs. EHTs with both hiPSC-CMs and hiPSC-CFs exhibit slower beating frequencies and enhanced contractile force compared to those composed of hiPSC-CMs alone. The modified protocol may help better characterise the interplay between different cell types in the myocardium and their contribution to structural remodelling and cardiac fibrosis. </ns3:p>
No takes yet. Share an insight, caveat, or question.
Cumberland et al. (2023) studied In vitro cardiac disease and fibrosis modeling using human iPSC-derived engineered heart tissues (EHTs) (n=6). Incorporation of quiescent human iPSC-derived cardiac fibroblasts (hiPSC-CFs) into hiPSC-derived cardiomyocyte (hiPSC-CM) engineered heart tissues vs. Engineered heart tissues composed of hiPSC-CMs alone (without hiPSC-CFs) was evaluated on Contractile force (normalized to cross-sectional area) and contraction amplitude at day 15 of EHT culture (Approximate 5-fold increase in normalized force and 30% greater average contraction amplitude). Incorporating hiPSC-derived cardiac fibroblasts into cardiomyocyte engineered heart tissues increased normalized contractile force approximately 5-fold and contraction amplitude by 30%.
Synapse has enriched 10 related papers. Consider them for comparative context: